Mequon firm receives another $1.2 million for cancer drug

ENDECE, a Mequon biopharmaceutical company focused on cancer research and drug discovery, has received $1.2 million in funding from a group of private investors. The money will be used to further the development of the company's lead compound, NDC-1308, which the company says shuts down a tumor's ability to survive by targeting molecular "bioswitches" that control metabolic pathways within cells. (MILWAUKEE BUSINESS JOURNAL, 7/21)